Harrow, Inc. has grown revenue 39% a year over three years and 35% a year over five. Revenue growth, 3-year annual rate: +39% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +35%, growth has picked up over the last three years. Years of annual history on file: 27, FY1999 to FY2025, as filed.

HROWHarrow, Inc.

Healthcare

$29.36-34% 1Y

$29.36

$29.0352 weeks$54.80

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +21% year on year, but operating margin narrowing (−11.0 points).

1 good, 1 to watch, 1 without data

Revenue trend+21% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +35% a year.

Margin direction−11.0 points operating

Trailing-twelve-month operating margin, -6.9% now against 4.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 3% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is HROW growing?

Harrow, Inc. has grown revenue 39% a year over three years and 35% a year over five.

+39%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +35%
Revenue growth, 5-year rate · +39% over three · growth has picked up over the last three years
Years of annual history on file: 27
Years of annual history on file · FY1999 to FY2025, as filed

Details›